Search results: Sage Journals

Open accessResearch articleFirst published September, 2016

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Ludwig Kappos, Nicola De Stefano, Mark S Freedman [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2018

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Douglas L. Arnold, Shulian Shang, Qunming Dong [...]

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published February, 2017

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Tomas Uher, Eva Havrdova, Lukas Sobisek [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published May, 2019

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b

Douglas S Goodin, Anthony T Reder, Anthony L Traboulsee [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2026

Real-world effectiveness and safety of ofatumumab in multiple sclerosis: a longitudinal study integrating clinical,cognitive,and MRI outcomes

Stefano Ziccardi, Damiano Marastoni, Pietro Biasi [...]

Therapeutic Advances in Neurological Disorders

Open accessReview articleFirst published August, 2017

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

Gavin Giovannoni, Davorka Tomic, Jeremy R Bright [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published August, 2021

Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis

Laura Ferrè, Andrea Mogavero, Ferdinando Clarelli [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2019

Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?

H.N. Beadnall, C. Wang, W. Van Hecke [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published June, 2015

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations

Douglas L Arnold, David Li, Marika Hohol [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open accessResearch articleFirst published 2021

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

Kimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published September, 2016

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Ludwig Kappos, Nicola De Stefano, Mark S Freedman [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2018

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Douglas L. Arnold, Shulian Shang, Qunming Dong [...]

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published February, 2017

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Tomas Uher, Eva Havrdova, Lukas Sobisek [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published May, 2019

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b

Douglas S Goodin, Anthony T Reder, Anthony L Traboulsee [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2026

Real-world effectiveness and safety of ofatumumab in multiple sclerosis: a longitudinal study integrating clinical,cognitive,and MRI outcomes

Stefano Ziccardi, Damiano Marastoni, Pietro Biasi [...]

Therapeutic Advances in Neurological Disorders

Open accessReview articleFirst published August, 2017

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

Gavin Giovannoni, Davorka Tomic, Jeremy R Bright [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published August, 2021

Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis

Laura Ferrè, Andrea Mogavero, Ferdinando Clarelli [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2019

Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?

H.N. Beadnall, C. Wang, W. Van Hecke [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published June, 2015

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations

Douglas L Arnold, David Li, Marika Hohol [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open accessResearch articleFirst published 2021

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

Kimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao [...]

Therapeutic Advances in Neurological Disorders